Phenotypic drug susceptibility testing of rapid growing mycobacteria and the issue of antibiotic stability

Nils Wetzstein; Thomas A Wichelhaus

doi:10.1016/j.diagmicrobio.2021.115555

Phenotypic drug susceptibility testing of rapid growing mycobacteria and the issue of antibiotic stability

Diagn Microbiol Infect Dis. 2022 Jan;102(1):115555. doi: 10.1016/j.diagmicrobio.2021.115555. Epub 2021 Sep 24.

Authors

Nils Wetzstein¹, Thomas A Wichelhaus²

Affiliations

¹ Department of Internal Medicine, Infectious Diseases, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany. Electronic address: nils.wetzstein@kgu.de.
² Institute of Medical Microbiology and Infection Control, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.

PMID: 34678713
DOI: 10.1016/j.diagmicrobio.2021.115555

Abstract

Phenotypic drug susceptibility testing is a valuable tool to guide therapy in rapid growing mycobacteria. Beta lactams, however, exhibit insufficient stability during a 5-day incubation period in minimal inhibitory concentration (MIC) testing as well as in time kill kinetics experiments. This might lead to false minimal inhibitory concentrations and inadequate therapeutic decisions.

Keywords: Drug susceptibility testing; M. abscessus; NTM; Non–tuberculous mycobacteria; Rapid growing mycobacteria.

MeSH terms

Anti-Bacterial Agents / pharmacology*
Drug Resistance, Multiple, Bacterial
Drug Stability
Humans
Microbial Sensitivity Tests
Nontuberculous Mycobacteria / drug effects*
Time Factors

Substances

Anti-Bacterial Agents